Гепатромбин Г

Quick links

Choose a section

Quick links to important sections

Advertisements

Гепатромбин Г

Selected form

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Гепатромбин Г

Property Description
Active Ingredients Heparin sodium, Prednisolone acetate, Lauromacrogol 600
Form Ointment and Rectal Suppositories
Pharmacological Class Antihemorrhoidal Agents (Combination)
Route of Administration Local (Topical/Rectal)
Origin Semi-Synthetic and Synthetic

1. The Tri-Active Formulation: Defining Гепатромбин Г’s Class

Гепатромбин Г is a combined pharmaceutical preparation specifically designed for local application in proctology, functioning as a multi-action therapeutic agent. Professionally, this product is classified as an antihemorrhoidal agent. Its unique structure integrates active ingredients from three distinct pharmacological groups: an anticoagulant, a glucocorticosteroid, and a local anesthetic.

This multi-component strategy is clinically recognized for its utility in managing complex local symptoms, focusing on the use of complementary agents for targeted symptomatic relief. The product is derived from a mix of synthetic and semi-synthetic origin.


2. Composition and Forms: Heparin, Prednisolone, and Lauromacrogol 600

The medication's three essential active ingredients are Heparin sodium, Prednisolone acetate, and Lauromacrogol 600 (Polidocanol). Heparin is responsible for antithrombotic action, Prednisolone acetate delivers a potent anti-inflammatory action, and Lauromacrogol 600 provides rapid local anesthetic action and is noted for its sclerosing properties.

Heparin is utilized topically for its ability to inhibit localized clot formation, a key property in such treatments. The inclusion of Lauromacrogol 600 as an anesthetic and sclerosing agent is a distinguishing feature of this formulation compared to simpler topical corticosteroid combinations. The preparation is available for the local route of administration as an ointment and as rectal suppositories.


3. General Therapeutic Aim: What is its Purpose?

The overall purpose of Гепатромбин Г is to provide comprehensive, rapid multi-symptom relief, often employed in scenarios involving acute, inflamed tissue discomfort. By combining anti-clotting, swelling reduction, and pain numbing effects, the preparation effectively minimizes inflammation, alleviates associated discomfort, and provides support against localized blood vessel complications. This coordinated action is the general therapeutic aim of the formulation.

Advertisements

What side effects are possible with Гепатромбин Г?

Possible side effects and safety information

Official safety documentation for this medicine focuses primarily on localized reactions and clear restrictions on use based on the patient’s known allergies and the condition of the application site.

Adverse Reactions

The documented adverse events are primarily related to the area of application. The frequency of these reactions is not formally classified in available regulatory summaries.

Key System-Organ Classes and Reactions:

  • Skin and Subcutaneous Tissue Disorders: Localized reactions, which may include skin hypersensitivity or allergic manifestations at the site of application.
  • Immune System Disorders: Hypersensitivity reactions.

Safety-Related Restrictions and Limitations

Safety data defines specific limitations and situations in which the medicine must not be used (contraindications):

Contraindications (Must Not Be Used):

  • Hypersensitivity: Known allergy or hypersensitivity to any of the active substances (Sodium Heparin, Prednisolone, Lauromacrogol 400) or any of the inactive ingredients/excipients.
  • Application Site Condition: The medicine is restricted from use on damaged skin, open wounds, or tissue that is infected with bacterial, viral, or fungal pathogens.

Safety Notes on Exposure:

Regulatory documentation indicates that prolonged use or application over extensive skin surface areas carries a theoretical risk of systemic effects. This possibility is related to the absorption of the corticosteroid component (Prednisolone) into the bloodstream, which mandates caution regarding the duration and extent of treatment.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for this local-application combination preparation is defined by the potential for systemic exposure to the Prednisolone acetate (glucocorticosteroid) component. This risk is primarily associated with excessive, prolonged use, or application over a large surface area.

Overdose Scope
Documented Presentations Clinical manifestations may include Cushing's syndrome, hyperglycemia, and glucosuria resulting from systemic absorption.
Severe Outcome The most severe documented regulatory concern is the risk of reversible hypothalamic-pituitary-adrenal (HPA) axis suppression.
Population Notes Pediatric patients are officially documented as more susceptible to systemic toxicity, including the potential for intracranial hypertension.

Management of documented overexposure focuses on reducing systemic absorption. If HPA axis suppression is confirmed by official laboratory tests, gradual withdrawal of the drug or reduced frequency of application is the required procedural step. No specific antidote is known for the systemic effects of the glucocorticosteroid, making symptomatic and supportive treatment the primary approach.

Immediate medical attention is required for suspected accidental ingestion of the product. In such cases, or if severe symptoms such as collapse or respiratory distress are observed, regulatory guidance mandates immediate contact with emergency services or a Poison Control Center.

Advertisements

Therapeutic Uses of Гепатромбин Г

The combination product Гепатромбин Г is applied in clinical settings that involve acute or unstable symptom patterns associated with hemorrhoidal disease. The core therapeutic context is aligned with domains involving heightened symptom expression, where supportive symptom management via locally applied agents is appropriate.

The medication is commonly used across conditions presenting with acute episodes of internal and external hemorrhoids, and for symptomatic support with anal fissures. It helps address symptom clusters that may become intense or disruptive, such as pronounced localized pain, persistent discomfort, and severe burning sensation.

The formulation is relevant in contexts marked by increased discomfort where supportive symptom management is appropriate. Specifically, it is applied in addressing symptoms related to inflammatory or irritative states and the physiological strain of localized vascular complications like thrombosed hemorrhoids.

“This provides support that helps ease the overall symptom load and assists with maintaining functional stability.”

This multi-faceted symptomatic assistance supports patients during difficult episodes by easing distress and is often used during phases when symptoms become more noticeable, or in the setting of postoperative symptomatic assistance.


Quick Fact: Relevant for Localized Pain, Swelling, and Vascular Complications

Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Гепатромбин Г

The use of Гепатромбин Г (a combination of Heparin, Prednisolone, and Lauromacrogol 600) is governed by strict regulatory constraints that define who may and who must not use the medicine. These rules are based on formal government prescribing information.

Populations for whom use is contraindicated

The medicine is strictly contraindicated (must not be used) in patients with the following conditions or characteristics:

  • Hypersensitivity: Known allergy or severe reaction to any of the active substances or excipients in the product.
  • Local Infections: Presence of local viral, bacterial, or fungal skin infections, as well as syphilis or tuberculosis in the area to be treated.
  • Bleeding Risk: Conditions associated with a predisposition to bleeding (hemorrhagic diathesis) or active bleeding.
  • Tumors and Wounds: Presence of tumors or application to open wounds or mucous membranes.

Restricted and Age-Related Use

  • Pregnancy and Lactation: Use is generally contraindicated during the first trimester of pregnancy. During the second and third trimesters, it is restricted and permitted only after careful medical evaluation. Use during breastfeeding is not recommended.
  • Children and Adolescents: Use in individuals under 18 years of age is typically not established or not recommended due to a lack of sufficient clinical data.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The primary focus of official interaction warnings for Гепатромбин Г centers on the risk of bleeding when combined with other agents that affect blood clotting. The combination of this product with several classes of drugs is subject to restrictions due to the potential for severe adverse effects.

Contraindicated and High-Risk Combinations:

  • Anticoagulants and Anti-platelet Drugs: The simultaneous use of other anticoagulants (e.g., heparin, warfarin, or direct oral anticoagulants), thrombolytic agents, or anti-platelet drugs (e.g., aspirin) is generally discouraged. This combination significantly increases the risk of local and systemic bleeding complications due to additive effects on the coagulation cascade or platelet function.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Combining the product with specific NSAIDs, such as indomethacin and phenylbutazone, is subject to contraindication. This interaction is rooted in the potential for NSAIDs to displace the heparin component from its protein binding, which intensifies its anticoagulant effect and elevates the risk of hemorrhage.

Combinations Requiring Caution:

  • Rectally Administered Medications: Concurrent administration of other products via the rectal route, including corticosteroids (glucocorticoids), should be approached with caution. This co-administration may result in a mutual enhancement of the local therapeutic effect or an increased absorption of the active components of one or both drugs. Close supervision is necessary to monitor for any unintended systemic effects.
Advertisements

Mechanism of Action

Modulating the Clotting Pathway

One active component, Heparin, acts as an indirect inhibitor by significantly enhancing the activity of the plasma protein Antithrombin III. This mechanism limits the activity of key coagulation factors (specifically Factor Xa and Thrombin), which reduces the formation of localized fibrin clots and supports local microcirculation.


Supporting Tissue Regeneration and Repair

The mechanism of action includes Dexpanthenol, which is rapidly converted into Pantothenic Acid (Vitamin B5). This substance is vital for cellular metabolism and serves as a cofactor necessary for the synthesis of new cells. This action promotes the proliferation of epithelial and connective tissues, contributing to the structural organization of affected vascular and perivascular tissue.


Addressing Localized Fluid Dynamics

A third core mechanism involves Allantoin, which functions as a modulator of tissue fluid dynamics. This component influences capillary permeability, the process by which fluid moves out of blood vessels. This mechanism limits the leakage of interstitial fluid into the surrounding tissues, resulting in a decrease in localized fluid volume.

Advertisements

Dosage and Administration Information

How to Use Гепатромбин Г: Administration Parameters

Гепатромбин Г is for local and rectal administration only, using its available forms: the ointment (for both external and internal use) and rectal suppositories (for internal use). The administration procedure focuses on hygiene and precise dosage.

Feature Description
Route Local (Topical/Rectal)
Dosing Schedule Ointment: Apply a column approx 2 cm long. Suppository: Insert one suppository.
Frequency Pattern Acute phase: 2 to 4 times daily. Maintenance: 1 to 2 times daily.
Duration Limit Must not exceed 7 days.

The drug is administered after a bowel movement and subsequent local hygiene, ensuring the area is clean for application. For internal use of the ointment, the provided screw-on applicator is used to deliver the standardized dose. The protocol begins with a frequent schedule to address acute symptomatic periods, but the total course of use is strictly limited to seven days. This restriction is a standard parameter for the formulation, especially due to the prednisolone acetate component. The reduction from the maximum daily frequency to a lower maintenance dose occurs before the treatment is entirely discontinued. The established protocols apply to adults, as there are no established dose protocols for pediatric patients.

Advertisements

Recent Clinical Evidence

Evidence for Symptom Management in Hemorrhoidal Disease

Research exploring how symptoms change over time in study participants has focused on adult outpatients with acute or chronic hemorrhoidal symptoms. The research base includes short-term Randomized Controlled Trials (RCTs) and observational studies that examined outcomes related to localized pain, anal discomfort, itching, burning, and rectal bleeding. These studies, often regionally focused, describe patterns observed during the typically short follow-up periods (e.g., up to 14 days) when the combination was administered versus non-active comparators. Research provides context but not individual predictions; long-term outcomes beyond the acute window are not fully established, and large-scale international systematic reviews are limited.


Evidence for Acute Vascular Complications and Anal Fissures

The product was also studied for more specific conditions. For thrombophlebitis of hemorrhoidal veins (thrombosed hemorrhoids), evidence consists primarily of clinical observation and case series examining changes in severe localized pain and swelling. Data for this acute condition are still emerging, and certainty remains low due to the lack of dedicated controlled trials that rigorously compare this topical combination against alternatives.

For conditions like anal fissures and related inflammatory states, the research is mainly based on clinical observation. Studies examined outcomes such as fissure-associated pain and changes in local inflammation. The evidence appears limited, often relying on the pharmacological rationale of its components rather than dedicated trials of the combined product for these specific indications.


Research Gaps and Uncertainty

Data for certain groups remain insufficient, and research has primarily focused on the general adult population. There are few data available for special populations such as pediatric patients or pregnant populations experiencing hemorrhoidal disease. The evidence highlights what is known and what is still uncertain: research quality varies across studies, follow-up durations are limited, and findings describe group patterns, not personal outcomes. More high-quality comparative trials are needed to strengthen the evidence base.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Гепатромбин Г (FAQ)


Q: What are the most commonly reported side effects of Гепатромбин Г?

Official documents describe adverse reactions as primarily localized, which may include skin hypersensitivity or allergic manifestations at the application site. Since this is a topical medicine, most concerns are related to the area of use. Regulatory summaries available do not formally specify the frequency of these reactions (e.g., classifying them as common or uncommon).


Q: Is it normal to feel a slight burning sensation when first using Гепатромбин Г?

Official information lists localized reactions and hypersensitivity at the application site as potential adverse events. Patients who experience burning or persistent discomfort may refer to the product's official leaflet for guidance on local reactions.


Q: Can Гепатромбин Г be used by pregnant women?

According to official documentation, the use of this product is contraindicated (must not be used) during the first trimester of pregnancy. Use during the second and third trimesters is restricted and permitted only after a careful medical evaluation of the potential benefits and risks.


Q: Is it possible to use Гепатромбин Г while breastfeeding?

Regulatory documents state that use during breastfeeding is not recommended. This recommendation is based on the lack of established clinical data concerning the potential transfer of the active components into breast milk.


Q: Can children or adolescents use Гепатромбин Г?

Official documentation indicates that the use of this medicine in individuals under 18 years of age is typically not established or not recommended. This restriction is due to a lack of sufficient clinical data regarding safety and efficacy in pediatric and adolescent patient groups.


Q: Does Гепатромбин Г address the pain, the swelling, or both?

The formulation is classified as a combined pharmaceutical preparation that incorporates active ingredients with multiple therapeutic effects. Regulatory documents describe that the ingredients provide local anesthetic action (related to pain relief) and anti-inflammatory action (related to swelling reduction), alongside antithrombotic properties.


Q: Can Гепатромбин Г be used for conditions other than hemorrhoids?

Official therapeutic indications for the product extend beyond general hemorrhoidal disease. The medicine is also indicated for the treatment of thrombophlebitis of hemorrhoidal veins and inflammatory states related to anal fissures.


Q: What should I do if I forget to use Гепатромбин Г at the regular time?

Regulatory documents typically provide guidance for missed applications. The regulatory guidance indicates that if an application is forgotten, continuation with the next scheduled dose is the expected procedure. The guidance states that a double dose should not be applied to compensate for the missed one.


Q: Can long-term use of Гепатромбин Г cause skin thinning?

Regulatory documents and warnings address the use of this product due to its corticosteroid component. Warnings state that prolonged use beyond the recommended duration (which is typically seven days) or application over extensive skin areas carries a risk of systemic effects and local skin reactions, such as skin atrophy (thinning).


Q: Can Гепатромбин Г interact with alcohol or certain foods?

The official documentation focuses primarily on significant interactions with other medicinal products, such as anticoagulants and specific NSAIDs. No specific warnings regarding interactions with alcohol or common foods are cited in the available regulatory documents for this product.


Q: What should I do if I accidentally swallow a small amount of the ointment?

In case of accidental ingestion of the ointment, official documentation describes the appropriate procedure as seeking immediate medical attention and following local poisoning guidance.


Q: Are there ingredients in Гепатромбин Г that can cause allergic reactions?

Yes, the official labeling lists hypersensitivity as a primary contraindication. Hypersensitivity is listed as a primary contraindication, meaning the medicine must not be used by patients with a known allergy or severe reaction to any of the active or inactive components (excipients) used in the formulation. All components are listed in the official documents.


Q: Does using Гепатромбин Г make it difficult to drive or operate machinery?

The regulatory labeling, which addresses potential effects on daily activities, indicates that the medicine has no known influence or a negligible influence on the ability to drive or safely operate machinery.


Q: Why do doctors prescribe Гепатромбин Г for anal fissures?

Anal fissures are listed as an official therapeutic indication for the product. The pharmacological properties of its components—specifically local anesthetic and anti-inflammatory effects—are considered relevant to managing the pain and inflammation associated with fissure-related conditions.


Q: Can people with liver or kidney problems use Гепатромбин Г?

Because the product contains a corticosteroid, official warnings typically address the possibility of systemic absorption. Caution may be advised in patients with severe hepatic or renal impairment. In such cases, use is subject to the careful evaluation of a healthcare professional.


Q: How should I dispose of unused Гепатромбин Г?

The official instruction for patients is to dispose of any unused or expired medicine in accordance with local regulatory requirements for pharmaceutical waste. Regulatory guidance indicates that medication should not be disposed of via regular household trash or wastewater systems.


Q: What kind of ingredients are used as inactive components or carriers in Гепатромбин Г?

Official regulatory documents provide a complete list of inactive components, known as excipients. These substances, such as carriers, stabilizers, and preservatives, are used in the formulation alongside the active ingredients (heparin, prednisolone, and lauromacrogol) to create the final product.


Q: Does Гепатромбин Г treat varicose veins in other parts of the body?

The medicine is officially indicated for local proctological conditions such as hemorrhoids and related vascular issues in that area. It is not listed in the official therapeutic indications for the treatment of varicose veins located in other regions of the body.


Q: What are the physical characteristics of the ointment (color, consistency)?

The regulatory documents describe the ointment as a specific pharmaceutical form in terms of its appearance. It is typically described as a homogeneous, yellowish-white, or white substance with a smooth consistency.

Advertisements

How should Гепатромбин Г be stored and disposed of?

Storage and Disposal of Гепатромбин Г

Гепатромбин Г must be stored at a strictly controlled room temperature, specifically between 15 C and 25 C, and must be protected from light. This mandates that the product must not be refrigerated or frozen.

Stability and Child Safety

The total shelf-life is 3 years; however, once the package is opened, the ointment must be used within 28 days. Throughout storage, the opened tube must be kept tightly closed and the medicine must always be stored in a location inaccessible to children.

Disposal

Official regulatory documents do not specify household disposal procedures for unused or expired product. Patients must dispose of any remaining medicine in accordance with local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Гепатромбин Г found in:

A-Z Index: